Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31019735 | 0.86 | CYP1A2 (0.75) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL24162675 | 0.84 | CYP1A2 (0.73) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL2071589 | 0.83 | SMN1; SMN2 (1.00) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL9672301 | 0.83 | SMN1; SMN2 (0.74) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL876603 | 0.83 | SMN1; SMN2 (0.73) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL9545487 | 0.83 | CYP1A2 (0.70) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL15057794 | 0.79 | SMN1; SMN2 (0.67) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL24162679 | 0.79 | SMN1; SMN2 (0.67) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL876428 | 0.78 | KDM4E (0.72) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL12732952 | 0.77 | CYP1A2 (0.63) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348448-A1 | PYRAZOLE ACYLHYDRAZONE CONTAINING TRIFLUOROMETHYLTHIADIAZOLE UNITS, PREPARATION METHOD AND USE THEREOF | NANTONG UNIVERSITY (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348448-A1 | PYRAZOLE ACYLHYDRAZONE CONTAINING TRIFLUOROMETHYLTHIADIAZOLE UNITS, PREPARATION METHOD AND USE THEREOF | NANTONG UNIVERSITY (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2022002193-A1 | PREPARATION METHOD FOR AND APPLICATION OF PYRAZOLE ACYLHYDRAZONE CONTAINING TRIFLUOROMETHYL THIADIAZOLE UNIT | 南通大学 | 2022-01-06 | — | — | WO | disclosed |
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| CN-101687790-B | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2(MGLU2 receptor) | ABBVIE INC | 2015-02-11 | — | — | CN | disclosed |
| EP-2167464-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | Abbott GmbH & Co. KG (DE) | 2010-03-31 | — | — | EP | disclosed |
| CN-101687790-A | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2(MGLU2 receptor) | ABBOTT GMBH & CO KG | 2010-03-31 | — | — | CN | disclosed |
| WO-2008145616-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | ABBOTT GMBH & CO. KG (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348448-A1 | PYRAZOLE ACYLHYDRAZONE CONTAINING TRIFLUOROMETHYLTHIADIAZOLE UNITS, PREPARATION METHOD AND USE THEREOF | AADAC, DDT, MLYCD | CYP1A2 1494/4885CYP2C19 1684/4885CYP2C9 854/4885 |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | GRM2, GRIN2C, GRM1 | CYP1A2 1751/4885CYP2C19 2357/4885CYP2C9 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.